Key result
ARNI reduces hospitalization and mortality in HFrEF.
Why the study?
Does a combined neprilysin inhibitor and angiotensin receptor blocker reduce hospitalization and mortality in patients with systolic heart failure?
Does a combined neprilysin inhibitor and angiotensin receptor blocker reduce hospitalization and mortality in patients with systolic heart failure?
A novel combined neprilysin inhibitor and angiotensin receptor blocker reduces hospitalization and mortality in systolic heart failure, though implementation faces challenges regarding patient selection, cost, and side effects.
May support ARNI use in HFrEF; leaves open optimal selection and long-term outcomes in broader populations.
Biologically active natriuretic peptides (NPs) are an integral part of cardiac homeostasis as they help to maintain sodium and fluid balance. When homeostasis is perturbed by neurohormonal activation in heart failure, levels of NPs rise in response. Neprilysin (NEP) is a naturally occuring enzyme that breaks down NPs. Scientists have recently discovered a novel pharmacologic agent that combines a NEP inhibitor and an angiotensin receptor blocker. In a large clinical trial, this new drug was found to reduce hospitalization and mortality in systolic heart failure. The challenges of implementing this therapy include patient selection, cost, and risk of side effects including angioedema and Alzheimer's disease.
No takes yet. Share an insight, caveat, or question.
Owens et al. (2016) conducted a review in Systolic heart failure. Neprilysin inhibitor and angiotensin receptor blocker combination was evaluated on Hospitalization and mortality. A novel pharmacologic agent combining a neprilysin inhibitor and an angiotensin receptor blocker was found to reduce hospitalization and mortality in systolic heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: